Home / Market News / $NVS
fiscal.ai Corporate Catalyst Impact 85/100 ● negative

Novartis Phase III ORION-4 Trial of Pelacarsen Misses Primary Endpoint

Nov 2, 2026, 2:02 PM UTC · Primary ticker $NVS

Novartis announced that its Phase III ORION-4 trial for pelacarsen failed to meet its primary endpoint, indicating a significant setback for the drug's development. This news is negative for Novartis's cardiovascular pipeline and could impact future revenue projections for the company.

Novartis reported that its Phase III ORION-4 trial for pelacarsen, a drug aimed at cardiovascular disease, did not achieve its primary endpoint. This is a significant clinical setback, as Phase III trials are the final stage before regulatory submission. The failure means that pelacarsen is unlikely to be approved for its intended use, representing a loss of potential future revenue and a blow to Novartis's cardiovascular pipeline. For traders, this implies short-term negative pressure on NVS stock due to the diminished prospects of a key pipeline asset. Long-term, it forces Novartis to re-evaluate its cardiovascular strategy and potentially allocate resources to other drug candidates.

$NVS negative Pelacarsen trial failure
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.